Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has provided an update.
Cosmo Pharmaceuticals N.V. has announced a groundbreaking clinical study to evaluate the integration of its Medtronic GI Genius™ endoscopy module with Apple Vision Pro at Rush University Medical Center. This innovative approach aims to enhance real-time AI-supported insights during colonoscopy procedures, potentially setting a new standard in interventional medicine. The study’s outcomes will support Cosmo’s FDA approval application, marking a significant step in the fusion of clinical AI and spatial computing in endoscopy.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF113.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a pharmaceutical company focused on revolutionizing healthcare by developing innovative products in healthtech/AI, dermatology, gastroenterology, and contract manufacturing. Founded in 1997 and headquartered in Dublin, Ireland, with branches in the USA and Italy, Cosmo collaborates with global partners like Medtronic and Sun Pharma to commercialize its products.
Average Trading Volume: 25,335
Current Market Cap: CHF939.5M
See more data about COPN stock on TipRanks’ Stock Analysis page.